This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
DE Addington , C Pantelis , M Dineen , I Benattia , (2004). Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. Journal of Clinical Psychiatry 65, 1624–1633.
NC Andreasen , WT Carpenter Jr., JM Kane , RA Lasser , (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry 162, 441–449.
M Arato , R O'Connor , HY Meltzer (2002). A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. International Clinical Psychopharmacology 17, 207–215.
TRE Barnes (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672–676.
DG Daniel , DL Zimbroff , SG Potkin , KR Reeves , , for the Ziprasidone Study Group (1999). Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 20, 491–505.
M De Hert , R van Winkel , M Wampers , J Kane , (2007). Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophrenia Research 92, 68–73.
PJ Diggle , P Heagerty , KY Liang , SL Zeger (2001). Analysis of Longitudinal Data, 2nd edn.Oxford: Oxford University Press.
RC Hall (1995). Global assessment of functioning. A modified scale. Psychosomatics 36, 267–275.
CM Harding , GW Brooks , T Ashikaga , JS Strauss , (1987). The Vermont longitudinal study of persons with severe mental illness. II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. American Journal of Psychiatry 144, 727–735.
DW Heinrichs , TE Hanlon , WT Carpenter Jr. (1984). The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 10, 388–398.
MI Herz , WM Glazer , MA Mostert , MA Sheard , (1991). Intermittent vs maintenance medication in schizophrenia. Two-year results. Archives of General Psychiatry 48, 333–339.
S Hirsch , W Kissling , J Bauml , A Power , (2002). A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. Journal of Clinical Psychiatry 63, 516–523.
G Huber , G Gross , R Schuttler (1975). A long-term follow-up study of schizophrenia: psychiatric course of illness and prognosis. Acta Psychiatrica Scandinavica 52, 49–57.
PB Jones , TR Barnes , L Davies , G Dunn , (2006). Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63, 1079–1087.
RS Kahn , WW Fleischhacker , H Boter , M Davidson , (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085–1097.
JM Kane , DT Crandall , RN Marcus , J Eudicone , (2007). Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophrenia Research 95, 143–150.
SR Kay , A Fiszbein , LA Opler (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261–276.
P Keck Jr., A Buffenstein , J Ferguson , J Feighner , (1998). Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berlin) 140, 173–184.
HC Kraemer , GT Wilson , CG Fairburn , WS Agras (2002). Mediators and moderators of treatment effects in randomized clinical trials. Archives of General Psychiatry 59, 877–883.
AC Leon , CH Mallinckrodt , C Chuang-Stein , DG Archibald , (2006). Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 59, 1001–1005.
S Leucht , RR Engel , J Bauml , JM Davis (2007). Is the superior efficacy of new generation antipsychotics an artifact of LOCF? Schizophrenia Bulletin 33, 183–191.
JA Lieberman , TS Stroup , JP McEvoy , MS Swartz , (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209–1223.
SR Marder , SM Glynn , WC Wirshing , DA Wirshing , (2003). Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. American Journal of Psychiatry 160, 1405–1412.
A Marneros , A Deister , A Rohde , EM Steinmeyer , (1989). Long-term outcome of schizoaffective and schizophrenic disorders: a comparative study. I. Definitions, methods, psychopathological and social outcome. European Archives of Psychiatry & Neurological Sciences 238, 118–125.
MC Mauri , A Colasanti , M Rossattini , LS Volonteri , (2007). Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels. Pharmacopsychiatry 40, 89–92.
JP McEvoy , JA Lieberman , DO Perkins , RM Hamer , (2007). Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. American Journal of Psychiatry 164, 1050–1060.
J Modestin , A Huber , E Satirli , T Malti , (2003). Long-term course of schizophrenic illness: Bleuler's study reconsidered. American Journal of Psychiatry 160, 2202–2208.
AM Mortimer (2007). Symptom rating scales and outcome in schizophrenia. British Journal of Psychiatry Supplement 50, S7–14.
B Parsons , DB Allison , A Loebel , K Williams , (2009). Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophrenia Research. Published online: 25 March 2009. doi:10.1016/j.schres.2008.09.025.
RA Rosenheck , DL Leslie , J Sindelar , EA Miller , (2006). Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry 163, 2080–2089.
GM Simpson , JW Angus (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica (Suppl.) 212, 11–19.
GM Simpson , ID Glick , PJ Weiden , SJ Romano , (2004). Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. American Journal of Psychiatry 161, 1837–1847.
GM Simpson , P Weiden , T Pigott , S Murray , (2005). Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. American Journal of Psychiatry 162, 1535–1538.
MT Tsuang , RF Woolson , JA Fleming (1979). Long-term outcome of major psychoses. I. Schizophrenia and affective disorders compared with psychiatrically symptom-free surgical conditions. Archives of General Psychiatry 36, 1295–1301.
JB Willett , JD Singer , NC Martin (1998). The design and analysis of longitudinal studies of development and psychopathology in context: statistical models and methodological recommendations. Development and Psychopathology 10, 395–426.
MC Wu , PS Albert , BU Wu (2001). Adjusting for drop-out in clinical trials with repeated measures: design and analysis issues. Statistics in Medicine 20, 93–108.